- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The dose-corrected Cmax, Cmin and AUC values are similar to those of adults
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Laryngeal papillomatosis (human papilloma virus) |
|---|
|
| Chronically active hepatitis C |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Weight loss and growth inhibition are common in children. In children and adolescents, the following are reported more often: abnormalities at the injection site, fever, anorexia, vomiting, emotional lability, suicidal thoughts, suicide attempts.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Children and adolescent with severe psychiatric impairment, particularly severe depression, suicidal thoughts or suicide attempts in the previous history.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Suicidal behaviour was observed more often in children and adolescents than in adults (2.4% versus 1%). In children and adolescents, check for signs of thyroid function disorders every three months. It is recommended that the growth of children receiving ribavirin combined with interferon α-2b should be monitored. In children and adolescents, check for signs of thyroid function disorders every three months.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Colony stimulating factors | ||
|---|---|---|
| L03AA02 | ||
| L03AA14 | ||
| Interferons | ||
|---|---|---|
| L03AB11 | ||
| L03AB10 | ||
| Other immunostimulants | ||
|---|---|---|
| L03AX13 | ||
| L03AX15 | ||
| L03AX16 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Gonzalez-Peralta RP, et al, Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics, Hepatology, 2005, Nov;42(5), 1010-8
- Boxall EH, et al, Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone, J Med Virol, 2006, Jul;78(7), 888-95
- Dikici B, et al, Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study, J Gastroenterol Hepatol, 2004, Feb;19(2), 127-33
- Gurakan F, et al, Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection, Pediatr Infect Dis J, 2000, Jan;19(1), 52-6
- Helvaci M, et al, Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B, J Gastroenterol Hepatol, 2004, Jul;19(7), 785-91
- Torre D, et al, Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis, Clin Infect Dis, 1996, Jul;23(1):, 131-7
- Wirth S, et al, [Chronic hepatitis B. Treatment in childhood with alpha-interferon], Monatsschr Kinderheilkd., 1992, Oct;140(10), 775-9
- Merck Sharp & Dohme Limited, SPC IntronA (EU/1/99/127/011-014), Geraadpleegd 23 dec 2011, http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/000281/WC500034679.pdf
- CHMP, EPAr IntronA, Doc. Ref.: EMA/10685/2010, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000281/WC500034673.pdf
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
